close× Call Us (401) 455-6200

What is the Biogen BIIB037 Study?

This is a Phase 1b study researching an amyloid antibody drug, labeled BIIB037, as a potential treatment for patients with prodromal or mild Alzheimer's Disease, AD. Patients receive the drug or placebo through an IV in their arm once every 4 weeks for the first year. There is an optional second year of treatment in which the patient will be guaranteed to receive the study drug (no placebo).

Eligibility

The study is ongoing at the Memory and Aging Clinic at Butler Hospital, but is no longer enrolling subjects.

If you are interested in learning more about the Biogen BIIB037 study, please call (401) 455-6403 or send an e-mail to: memory@butler.org. Ask about the “Biogen BIIB037 study.”

More information on other current research studies at Butler Hospital.